ReviewACS omega2025
Harnessing Polymeric Dissolvable Microneedles: Precision Delivery of Therapeutics for Oral Ulcers.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral ulcers are a prevalent and recurrent condition that significantly impacts the patient's quality of life by causing pain, discomfort, and difficulty in eating, speaking, and brushing their teeth. These ulcers can be triggered by diverse etiologies, from trauma to autoimmune disorders, which complicate their management, and they often require targeted treatment to promote healing and alleviate pain. Conventional treatments, such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and topical analgesics, among others, rely on synthetic medications that provide temporary relief and require frequent reapplication, thereby limiting their effectiveness. Thus, the management of oral ulcers necessitates the need for innovative therapeutic approaches. Recent advancements in nanotechnology and transdermal drug delivery have led to the development of dissolving microneedles (MNs) loaded with nanotherapeutics for delivering active therapeutics directly to affected oral tissues as a novel strategy for treating oral ulcers. Dissolving MNs offer a minimally invasive, painless, and efficient method for delivering therapeutic agents directly to the ulcer site, enhancing drug bioavailability, and ensuring sustained release. These biodegradable MNs dissolve upon application, eliminating the need for repeated drug application and thereby improving patient compliance. The synergistic approach of nanotherapeutics encapsulated within dissolving MNs, including nanoparticles, exosomes, and liposomes, among others, effectively addresses the multifactorial nature of oral ulcers by ensuring localized treatment and mitigating the systemic side effects associated with conventional drug delivery methods. Taken together, this review aims to integrate the current knowledge of these innovative technologies while highlighting future directions for research and clinical applications in treating oral ulcers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.